Adenosine receptor 2a agonists target mouse CD11c+T-bet+ B cells in infection and autoimmunity

Russell C. Levack; Krista L. Newell; Berenice Cabrera-Martinez; Justin Cox; Andras Perl; Sheldon I. Bastacky; Gary M. Winslow

doi:10.1038/s41467-022-28086-1

Nature Communications (Jan 2022)

Adenosine receptor 2a agonists target mouse CD11c+T-bet+ B cells in infection and autoimmunity

Russell C. Levack,
Krista L. Newell,
Berenice Cabrera-Martinez,
Justin Cox,
Andras Perl,
Sheldon I. Bastacky,
Gary M. Winslow

Affiliations

Russell C. Levack: Department of Microbiology and Immunology, Upstate Medical University
Krista L. Newell: Department of Microbiology and Immunology, Upstate Medical University
Berenice Cabrera-Martinez: Department of Microbiology and Immunology, Upstate Medical University
Justin Cox: Department of Microbiology and Immunology, Upstate Medical University
Andras Perl: Department of Medicine, Division of Rheumatology, Upstate Medical University
Sheldon I. Bastacky: Department of Pathology, University of Pittsburgh School of Medicine
Gary M. Winslow: Department of Microbiology and Immunology, Upstate Medical University

DOI: https://doi.org/10.1038/s41467-022-28086-1
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 12

Abstract

Read online

CD11c+T-bet+ B cells have been linked with different autoimmune diseases, but targeting these cells has been challenging. Here the authors use an adenosine 2A receptor agonist to deplete these B cells and to inhibit or reverse autoimmune symptoms and pathology in mice.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal